XAIR - Beyond Air (XAIR) Stock Gains Almost 20% on FDA Approval
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Beyond Air (NASDAQ:XAIR) stock jumped nearly 20% in early trading and is trending on many social media websites. The company’s LungFit PH device, which treats some of the newborns who have respiratory failure, was approved by the Food and Drug Administration (FDA).
The company also reported a higher-than-expected loss for its fiscal fourth quarter and disclosed that it had $80.2 million of cash and cash equivalents as of March 31.
Beyond Air’s LungFit PH Device Received FDA Approval
Beyond Air disclosed that, on June 28, the FDA had approved its LungFit PH device for newborns with hypoxic respiratory failure who were born after nine months or nearly nine months of pregnancy. Infants with hypoxic respiratory failure have abnormally low levels of oxygen in their blood, while the amount of carbon dioxide in their blood is “close to normal.”
LungFit PH creates “on-demand nitric oxide from room air,” Beyond Air explained. The only device of its kind, it can provide “unlimited” nitric oxide to patients within a minute of its activation, according to the company. Nitric oxide “relaxes the inner muscles of the blood vessels, causing them to widen and increase circulation.”
“We believe the introduction of this groundbreaking system, LungFit PH, will transform the way nitric oxide is used by hospital staff and provide numerous benefits related to safety and cost,” said Beyond Air CEO Steve Lisi in a statement.
The company added that LungFit PH is “on track” to be approved by the EU’s drug and medical device regulator.
About Beyond Air
The company is also developing LungFit Pro which, according to its marketing material, can provide supplemental oxygen, is programmable, and can treat multiple patients. The LungFit GO is still undergoing testing but is a more portable version of the PRO. It delivers nitrous oxide in patients’ home and the company is in the early stages of developing it as a “ultra-high concentration gaseous NO (UNO) therapy for solid tumors.”
XAIR Stock and Financial Results
The company’s Q4 loss per share came in at $1.68, versus analysts’ average estimate of a $1.21 loss per share. It had no revenue in Q4 or in the previous three quarters. For its entire fiscal year, which ended on March 31, Beyond Air’s net loss came in at $44.4 million.
Heading into today. XAIR stock had tumbled nearly 40% so far this year.
On the publication date, Larry Ramer did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
More From InvestorPlace
- $200 Oil Sooner Than You Think – Buy This Now
- The Best $1 Investment You Can Make Today
- Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
- It doesn’t matter if you have $500 in savings or $5 million. Do this now.
The post Beyond Air (XAIR) Stock Gains Almost 20% on FDA Approval appeared first on InvestorPlace.